RxDoctor Payments Data

Randolph Nunag

Internal Medicine · Weeki Wachee, FLNPI 1417950148

Payments from drug & device makers

$1,320in general payments, 2019–2025

Across 40 payments — averaging $33.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$239
  • AstraZeneca$193
  • Stryker$167
  • Sanofi-aventis U.S. LLC$118
  • Novo Nordisk$106
  • GSK$105
  • plus $391 from 10 others

What the payments were for

  • Food & beverage$1,320100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,320 in reported general payments places this provider in the 70th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$127,767
Medicare patients
247
Services billed
1,391

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban80$104,372
OzempicSemaglutide44$61,698
JardianceEmpagliflozin23$40,572
JanuviaSitagliptin Phosphate19$29,287
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$17,094
MyrbetriqMirabegron11$13,204
XareltoRivaroxaban14$10,034
VascepaIcosapent Ethyl12$3,818
Metoprolol Succinate205$3,281
Levothyroxine Sodium291$3,175
Rosuvastatin Calcium170$2,909
Losartan Potassium266$2,888
Wixela InhubFluticasone Propion/Salmeterol13$2,842
Atorvastatin Calcium254$2,452
Fluticasone-SalmeterolFluticasone Propion/Salmeterol16$2,338

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$35$104,37280 claims
Novo NordiskOzempic$106$61,69844 claims
GSKTrelegy Ellipta$105$17,09425 claims
Johnson & JohnsonXarelto$84$10,03414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Weeki Wachee

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →